ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Core Insights - ARS Pharmaceuticals, Inc. announced that the European Patent Office upheld the validity of its patent EP 3678649, which covers nasal spray epinephrine formulations, including alkyl-glycoside [1] - The company's global intellectual property portfolio related to its product neffy provides coverage until at least 2039 [2] - The successful defense of two patents in different jurisdictions strengthens the company's position against future patent challenges [3] Patent Validity and Legal Outcomes - The EPO's unanimous decision supports the strength and validity of ARS Pharma's extensive patent portfolio [4] - Earlier this year, the United States Patent and Trademark Office upheld key claims for U.S. Patent No. 10,682,414, which pertains to treating type-1 hypersensitivity reactions with an epinephrine nasal spray [2][4] Product Information - Neffy is a nasal spray indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 33 lbs [5] - The product is designed to address limitations associated with epinephrine auto-injectors, such as needle fear and portability issues [13] Market Context - Approximately 40 million people in the U.S. experience type I allergic reactions, with 20 million diagnosed and treated for severe reactions in the last three years [13] - Despite the prevalence, only 3.2 million filled their active epinephrine auto-injector prescriptions in 2023, highlighting a significant market opportunity for neffy [13]